Particle.news
Download on the App Store
10 ARTICLES
·
15h ago

OpenAI Launches GPT-Rosalind, a Biology-Tuned AI for Drug Discovery

Access is tightly controlled to address biosecurity risks.

OpenAI logo is seen in this illustration taken May 20, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
A complex blue, glowing web of connections on a black background.
Image
Image

Overview

  • OpenAI's GPT-Rosalind, introduced Thursday, is live as a research preview for vetted U.S. enterprise users through ChatGPT, Codex, and the API.
  • The model helps researchers handle multi-step work such as evidence reviews, hypothesis generation, and experiment plans across papers, databases, and lab tools.
  • A free Life Sciences plugin for Codex connects to more than 50 scientific tools and public data sources, giving broader users a workflow layer even without full model access.
  • Company tests report top scores on the BixBench bioinformatics benchmark and strong results in a Dyno Therapeutics RNA task, though independent validation is still pending.
  • OpenAI lists partners including Amgen, Moderna, Thermo Fisher Scientific, the Allen Institute, and Novo Nordisk, and it enforces eligibility checks and biosecurity flags while tuning the model to be more skeptical of weak drug targets.